Analysis of Coagulation Cascade and Endothelial Cell Activation During Inhibition of Vascular Endothelial Growth Factor/Vascular Endothelial Growth Factor Receptor Pathway in Cancer Patients

Objective—The angiogenesis inhibitor SU5416 is a potent inhibitor of vascular endothelial growth factor (VEGF) receptor-1 and -2. VEGF may be involved in hemostasis by altering the hemostatic properties of endothelial cells. We analyzed the effects of SU5416 on the coagulation cascade and the vessel wall in patients with advanced cancer. Methods and Results—Markers for thrombin generation, activation of the protein C pathway, fibrinolysis, and endothelial cell activation were measured in patients with renal cell carcinoma, soft tissue sarcoma, or melanoma on days 0, 14, and 28 of treatment with SU5416. Three of 17 sampled patients developed a thromboembolic event in the fifth week of treatment. Markers for thrombin generation and fibrinolysis did not show significant changes. We observed a significant increase in endogenous thrombin potential and of parameters reflecting endothelial cell activation (von Willebrand antigen, soluble tissue factor, and soluble E-selectin) in all patients (P ≤0.001). In patients experiencing a thromboembolic event, endogenous thrombin potential, soluble tissue factor, and soluble E-selectin increased to a significantly greater extent (P =0.029, P =0.021, and P =0.007, respectively). Conclusions—VEGF is not only a permeability, proliferation, and migration factor, but it is also a maintenance and protection factor for endothelial cells.

[1]  G. Peters,et al.  Dose-finding and pharmacokinetic study of cisplatin, gemcitabine, and SU5416 in patients with solid tumors. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  M. Shibuya,et al.  Antiangiogenic effect by SU5416 is partly attributable to inhibition of Flt-1 receptor signaling. , 2002, Molecular cancer therapeutics.

[3]  M. Prins,et al.  Venous thromboembolism and occult malignancy. , 2001, Thrombosis research.

[4]  I. Zachary.  Signaling mechanisms mediating vascular protective actions of vascular endothelial growth factor. , 2001, American journal of physiology. Cell physiology.

[5]  K. Sugimachi,et al.  Failure in the detection of aberrant mRNA from the heterozygotic splice site mutant allele for protein S in a patient with protein S deficiency. , 2001, Thrombosis research.

[6]  J. Cherrington,et al.  The antiangiogenic protein kinase inhibitors SU5416 and SU6668 inhibit the SCF receptor (c-kit) in a human myeloid leukemia cell line and in acute myeloid leukemia blasts. , 2001, Blood.

[7]  V. V. van Hinsbergh,et al.  Vascular Endothelial Growth Factor Enhances the Expression of Urokinase Receptor in Human Endothelial Cells via Protein Kinase C Activation , 2001, Thrombosis and Haemostasis.

[8]  H. Verheul,et al.  Vascular endothelial growth factor-stimulated endothelial cells promote adhesion and activation of platelets. , 2000, Blood.

[9]  J. Cherrington,et al.  The angiogenesis inhibitor SU5416 has long-lasting effects on vascular endothelial growth factor receptor phosphorylation and function. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[10]  P. Carmeliet,et al.  Angiogenesis in cancer and other diseases , 2000, Nature.

[11]  Y. Nemerson,et al.  Tissue factor, the blood, and the arterial wall. , 2000, Trends in cardiovascular medicine.

[12]  G. Keller,et al.  VEGF nuclear accumulation correlates with phenotypical changes in endothelial cells. , 2000, Journal of cell science.

[13]  L. Zanetta,et al.  Expression of von Willebrand factor, an endothelial cell marker, is up‐regulated by angiogenesis factors: A potential method for objective assessment of tumor angiogenesis , 2000, International journal of cancer.

[14]  L. Bouter,et al.  von Willebrand factor, C-reactive protein, and 5-year mortality in diabetic and nondiabetic subjects: the Hoorn Study. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[15]  D. Y. Lee,et al.  Vascular Endothelial Growth Factor Governs Endothelial Nitric-oxide Synthase Expression via a KDR/Flk-1 Receptor and a Protein Kinase C Signaling Pathway* , 1999, The Journal of Biological Chemistry.

[16]  P. Gaffney,et al.  The Haemostatic Balance – Astrup Revisited , 1999, Pathophysiology of Haemostasis and Thrombosis.

[17]  M. Wolzt,et al.  Large amounts of vascular endothelial growth factor at the site of hemostatic plug formation in vivo. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[18]  M. Emerson,et al.  Endogenous Nitric Oxide Acts as a Natural Antithrombotic Agent In Vivo by Inhibiting Platelet Aggregation in the Pulmonary Vasculature , 1999, Thrombosis and Haemostasis.

[19]  D. Lefer,et al.  Vascular endothelial growth factor attenuates leukocyte–endothelium interaction during acute endothelial dysfunction: essential role of endothelium‐derived nitric oxide , 1999, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[20]  B. Binder,et al.  Vascular endothelial cell growth factor-induced tissue factor expression in endothelial cells is mediated by EGR-1. , 1999, Blood.

[21]  J. Fallon,et al.  Cooperation between VEGF and TNF-alpha is necessary for exposure of active tissue factor on the surface of human endothelial cells. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[22]  P. A. von dem Borne,et al.  Plasma TAFI Levels Influence the Clot Lysis Time in Healthy Individuals in the Presence of an Intact Intrinsic Pathway of Coagulation , 1998, Thrombosis and Haemostasis.

[23]  J. Loscalzo,et al.  Endothelial cells in physiology and in the pathophysiology of vascular disorders. , 1998, Blood.

[24]  J. Morser,et al.  Both Cellular and Soluble Forms of Thrombomodulin Inhibit Fibrinolysis by Potentiating the Activation of Thrombin-activable Fibrinolysis Inhibitor* , 1998, The Journal of Biological Chemistry.

[25]  B. Grinnell,et al.  Thrombomodulin-dependent anticoagulant activity is regulated by vascular endothelial growth factor. , 1998, Experimental cell research.

[26]  J. Isner,et al.  Vascular endothelial growth factor/vascular permeability factor produces nitric oxide-dependent hypotension. Evidence for a maintenance role in quiescent adult endothelium. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[27]  S. Mandriota,et al.  Vascular endothelial growth factor-induced in vitro angiogenesis and plasminogen activator expression are dependent on endogenous basic fibroblast growth factor. , 1997, Journal of cell science.

[28]  H. Hemker,et al.  Oral contraceptives and venous thrombosis: different sensitivities to activated protein C in women using second‐ and third‐generation oral contraceptives , 1997, British journal of haematology.

[29]  J. Isner,et al.  Vascular endothelial growth factor/vascular permeability factor augments nitric oxide release from quiescent rabbit and human vascular endothelium. , 1997, Circulation.

[30]  D. Harrison,et al.  Nitric oxide regulates vascular cell adhesion molecule 1 gene expression and redox-sensitive transcriptional events in human vascular endothelial cells. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[31]  P. Libby,et al.  Nitric oxide decreases cytokine-induced endothelial activation. Nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines. , 1995, The Journal of clinical investigation.

[32]  H. Dvorak,et al.  Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. , 1995, The American journal of pathology.

[33]  J. Pearson,et al.  Endothelial cell function and thrombosis. , 1994, Bailliere's best practice & research. Clinical haematology.

[34]  L. Orci,et al.  Vascular endothelial growth factor (VEGF) induces plasminogen activators and plasminogen activator inhibitor-1 in microvascular endothelial cells. , 1991, Biochemical and biophysical research communications.

[35]  D. Connolly,et al.  Vascular permeability factor: a tumor-derived polypeptide that induces endothelial cell and monocyte procoagulant activity, and promotes monocyte migration , 1990, The Journal of experimental medicine.

[36]  S. Moncada,et al.  ENDOGENOUS NITRIC OXIDE INHIBITS HUMAN PLATELET ADHESION TO VASCULAR ENDOTHELIUM , 1987, The Lancet.

[37]  J. Čejka.  Performance characteristics of a commercial kit for assay of factor viii-related antigen. , 1984, Clinical chemistry.

[38]  糸川 高史.  Antiangiogenic effect by SU5416 is partly attributable to inhibition of Flt-1 receptor signaling , 2003 .

[39]  R. Jain,et al.  During angiogenesis, vascular endothelial growth factor and basic fibroblast growth factor regulate natural killer cell adhesion to tumor endothelium. , 1996, Nature medicine.

[40]  H. Dvorak,et al.  Tumor-secreted vascular permeability factor increases cytosolic Ca2+ and von Willebrand factor release in human endothelial cells. , 1991, The American journal of pathology.